Aurora Investment Counsel Lowers Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Aurora Investment Counsel reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 37.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,054 shares of the medical equipment provider's stock after selling 11,340 shares during the quarter. Lantheus accounts for about 1.1% of Aurora Investment Counsel's holdings, making the stock its 27th largest holding. Aurora Investment Counsel's holdings in Lantheus were worth $2,091,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of LNTH. Signaturefd LLC boosted its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares during the period. GAMMA Investing LLC lifted its position in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 208 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares during the period. Kathleen S. Wright Associates Inc. purchased a new position in shares of Lantheus in the third quarter worth $51,000. Finally, Nkcfo LLC purchased a new stake in Lantheus during the 2nd quarter valued at $47,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

LNTH stock opened at $86.45 on Thursday. The firm has a market capitalization of $6.01 billion, a price-to-earnings ratio of 14.38 and a beta of 0.51. The firm has a 50 day moving average price of $103.76 and a 200-day moving average price of $96.59. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89.

Analysts Set New Price Targets

Several equities analysts have recently commented on LNTH shares. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Friday, November 8th. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Truist Financial reissued a "buy" rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. B. Riley lifted their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Finally, JMP Securities decreased their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.